Preventing Hepatitis B Reactivation During Anti‐CD20 Antibody Treatment in the Veterans Health Administration

A. Jasmine Bullard, Francesca E. Cunningham, Bryan D. Volpp, Elliott Lowy, Lauren A. Beste, Bernadette B. Heron, Mark Geraci, Julia M. Hammond, Kourtney LaPlant, Elise A. Stave, Marsha J. Turner, Meghan C. O’Leary, Michael J. Kelley, Christine M. Hunt – 28 August 2018 – Hepatitis B virus (HBV) reactivation may occur with high risk immunosuppression, such as anti‐cluster of differentiation (CD)20 antibodies (Abs). Appropriate HBV prophylaxis during anti‐CD20 Ab therapy averts hepatitis, chemotherapy disruption, and death.

Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early‐Stage Hepatocellular Carcinoma

Jonggi Choi, Gi‐Ae Kim, Seungbong Han, Woochang Lee, Sail Chun, Young‐Suk Lim – 28 August 2018 – We aimed to determine the surveillance performance of alpha‐fetoprotein (AFP), lectin‐reactive AFP (AFP‐L3), des‐gamma‐carboxy prothrombin (DCP), and their combinations for the early detection of hepatocellular carcinoma (HCC) by using prospectively collected longitudinal samples in patients at risk.

Splenectomy as Flow Modulation Strategy and Risk Factors of De Novo Portal Vein Thrombosis in Adult‐to‐Adult Living Donor Liver Transplantation

Ivan Linares, Nicolas Goldaracena, Roizar Rosales, Luis De la Maza, Moritz Kaths, Dagmar Kollmann, Juan Echeverri, Nazia Selzner, Stuart A. McCluskey, Gonzalo Sapisochin, Leslie B. Lilly, Paul Greig, Mamatha Bhat, Anand Ghanekar, Mark Cattral, Ian McGilvray, David Grant, Markus Selzner – 26 August 2018 – Portal vein thrombosis (PVT) is a severe complication after liver transplantation that can result in increased morbidity and mortality. Few data are available regarding risk factors, classification, and treatment of PVT after living donor liver transplantation (LDLT).

Subscribe to